Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors
暂无分享,去创建一个
R. Salazar | J. Soria | J. Armand | E. Deutsch | C. Massard | A. Oaknin | M. Majem | E. Fernández-García | M. Garcia | A. Soto | E. Deutsch | M. García